TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study.

doi:10.1002/ijc.35203

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study.

International journal of cancer - 1 Mar 2025

Bignotti Eliana, Simeon Vittorio, Ardighieri Laura, Kuhn Elisabetta, Marchini Sergio, Califano Daniela, Cecere Sabrina Chiara, Bugatti Mattia, Spina Anna, Scognamiglio Giosuè, Paracchini Lara, Russo Daniela, Arenare Laura, Tognon Germana, Lorusso Domenica, Beltrame Luca, D'Incalci Maurizio, Sartori Enrico, De Censi Andrea, Odicino Franco, Perrone Francesco, Chiodini Paolo, Pignata Sandro

Abstract excerpt

To date, there are no biomarkers that define a patient subpopulation responsive to bevacizumab (BEV), an effective treatment option for advanced ovarian carcinoma (OC). In the context of the MITO16A/MaNGO OV-2 trial, a Phase IV study of chemotherapy combined with BEV in first-line treatment of advanced OC, we evaluated TP53 mutations by next-generation sequencing and p53 expression by immunohistochemistry (IHC)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Bevacizumab

Share to Biomarkers, Tumor

Share to Mutation

Share to Ovarian Neoplasms

Share to Prognosis

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 39415516
DOI: 10.1002/ijc.35203
PMCID: PMC11701406

Genes

TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study.PMID 39415516Read ↗

Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.Semantic proximity Read ↗

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.Semantic proximity Read ↗

The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations.Semantic proximity Read ↗

Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)Semantic proximity Read ↗

Ovarian cancer in 2011: Mutations and non-inferiority analyses show a way forward.Semantic proximity Read ↗

TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.Semantic proximity Read ↗

TP53 Mutations in Breast and Ovarian Cancer.Semantic proximity Read ↗

TP53 mutations in epithelial ovarian cancerSemantic proximity Read ↗

Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis.Semantic proximity Read ↗

Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.Semantic proximity Read ↗

Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trialSemantic proximity Read ↗

Identification of TP53 mutations in circulating tumour DNA in high grade serous ovarian carcinoma using next generation sequencing technologies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.